Cargando…
Sequential tumor and dual immune targeted immunotherapy: anti-lymphoma activity of Rituximab with 4-1bb stimulation and PD-1 blockade
| Autores principales: | , , , , , , , , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
BioMed Central
2014
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4288390/ http://dx.doi.org/10.1186/2051-1426-2-S3-P106 |
| _version_ | 1782351962028638208 |
|---|---|
| author | Mueller, Antonia MS Hebb, Jonathan Sagiv-Barfi, Idit Marabelle, Aurelien Houot, Roch Rajapaksa, Amanda Czerwinski, Debra K Chang, Serena Chester, Cariad Sadaram, Mohith Waller, Erin Levy, Ronald Kohrt, Holbrook |
| author_facet | Mueller, Antonia MS Hebb, Jonathan Sagiv-Barfi, Idit Marabelle, Aurelien Houot, Roch Rajapaksa, Amanda Czerwinski, Debra K Chang, Serena Chester, Cariad Sadaram, Mohith Waller, Erin Levy, Ronald Kohrt, Holbrook |
| author_sort | Mueller, Antonia MS |
| collection | PubMed |
| description | |
| format | Online Article Text |
| id | pubmed-4288390 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2014 |
| publisher | BioMed Central |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-42883902015-01-15 Sequential tumor and dual immune targeted immunotherapy: anti-lymphoma activity of Rituximab with 4-1bb stimulation and PD-1 blockade Mueller, Antonia MS Hebb, Jonathan Sagiv-Barfi, Idit Marabelle, Aurelien Houot, Roch Rajapaksa, Amanda Czerwinski, Debra K Chang, Serena Chester, Cariad Sadaram, Mohith Waller, Erin Levy, Ronald Kohrt, Holbrook J Immunother Cancer Poster Presentation BioMed Central 2014-11-06 /pmc/articles/PMC4288390/ http://dx.doi.org/10.1186/2051-1426-2-S3-P106 Text en Copyright © 2014 Mueller et al.; licensee BioMed Central Ltd. http://creativecommons.org/licenses/by/4.0 This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated. |
| spellingShingle | Poster Presentation Mueller, Antonia MS Hebb, Jonathan Sagiv-Barfi, Idit Marabelle, Aurelien Houot, Roch Rajapaksa, Amanda Czerwinski, Debra K Chang, Serena Chester, Cariad Sadaram, Mohith Waller, Erin Levy, Ronald Kohrt, Holbrook Sequential tumor and dual immune targeted immunotherapy: anti-lymphoma activity of Rituximab with 4-1bb stimulation and PD-1 blockade |
| title | Sequential tumor and dual immune targeted immunotherapy: anti-lymphoma activity of Rituximab with 4-1bb stimulation and PD-1 blockade |
| title_full | Sequential tumor and dual immune targeted immunotherapy: anti-lymphoma activity of Rituximab with 4-1bb stimulation and PD-1 blockade |
| title_fullStr | Sequential tumor and dual immune targeted immunotherapy: anti-lymphoma activity of Rituximab with 4-1bb stimulation and PD-1 blockade |
| title_full_unstemmed | Sequential tumor and dual immune targeted immunotherapy: anti-lymphoma activity of Rituximab with 4-1bb stimulation and PD-1 blockade |
| title_short | Sequential tumor and dual immune targeted immunotherapy: anti-lymphoma activity of Rituximab with 4-1bb stimulation and PD-1 blockade |
| title_sort | sequential tumor and dual immune targeted immunotherapy: anti-lymphoma activity of rituximab with 4-1bb stimulation and pd-1 blockade |
| topic | Poster Presentation |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4288390/ http://dx.doi.org/10.1186/2051-1426-2-S3-P106 |
| work_keys_str_mv | AT muellerantoniams sequentialtumoranddualimmunetargetedimmunotherapyantilymphomaactivityofrituximabwith41bbstimulationandpd1blockade AT hebbjonathan sequentialtumoranddualimmunetargetedimmunotherapyantilymphomaactivityofrituximabwith41bbstimulationandpd1blockade AT sagivbarfiidit sequentialtumoranddualimmunetargetedimmunotherapyantilymphomaactivityofrituximabwith41bbstimulationandpd1blockade AT marabelleaurelien sequentialtumoranddualimmunetargetedimmunotherapyantilymphomaactivityofrituximabwith41bbstimulationandpd1blockade AT houotroch sequentialtumoranddualimmunetargetedimmunotherapyantilymphomaactivityofrituximabwith41bbstimulationandpd1blockade AT rajapaksaamanda sequentialtumoranddualimmunetargetedimmunotherapyantilymphomaactivityofrituximabwith41bbstimulationandpd1blockade AT czerwinskidebrak sequentialtumoranddualimmunetargetedimmunotherapyantilymphomaactivityofrituximabwith41bbstimulationandpd1blockade AT changserena sequentialtumoranddualimmunetargetedimmunotherapyantilymphomaactivityofrituximabwith41bbstimulationandpd1blockade AT chestercariad sequentialtumoranddualimmunetargetedimmunotherapyantilymphomaactivityofrituximabwith41bbstimulationandpd1blockade AT sadarammohith sequentialtumoranddualimmunetargetedimmunotherapyantilymphomaactivityofrituximabwith41bbstimulationandpd1blockade AT wallererin sequentialtumoranddualimmunetargetedimmunotherapyantilymphomaactivityofrituximabwith41bbstimulationandpd1blockade AT levyronald sequentialtumoranddualimmunetargetedimmunotherapyantilymphomaactivityofrituximabwith41bbstimulationandpd1blockade AT kohrtholbrook sequentialtumoranddualimmunetargetedimmunotherapyantilymphomaactivityofrituximabwith41bbstimulationandpd1blockade |